A Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Subcutaneous Injections of ABBV-257 in Subjects With Rheumatoid Arthritis

Phase 1

Completed

• Conditions: Rheumatoid Arthritis
• Interventions: Biological: ABBV-257; Biological: Placebo

• Registration Number: NCT02531178
• Lead Sponsor: AbbVie

Brief Summary

This is a Phase 1, randomized, double-blind, placebo-controlled, multiple dose study designed to assess the safety, tolerability, pharmacokinetics, and immunogenicity of different dose levels of ABBV-257 given with methotrexate. ABBV-257 or placebo will be administered once every other week (EOW) for a total of 4 doses. Subjects will continue on their stable dose of methotrexate weekly throughout participation in the study.

This study will be conducted in approximately 24 subjects in 3 dose groups, with 8 subjects per group. Within each group, 6 subjects will be randomized to receive ABBV-257 and 2 subjects will receive placebo. Subjects participating in one dose group will be ineligible to participate in another dose group in the study.

Detailed Description

Multiple dose study designed to assess the safety, tolerability, pharmacokinetics, and immunogenicity of different dose levels of ABBV-257 given with methotrexate.

Study Timeline

• Study Start: 2015-07
• Study First Submitted: 2015-07-14
• Study First Submitted QC: 2015-08-20
• Study First Posted: 2015-08-24
• Primary Completion: 2016-02
• Study Completion: 2016-02
• Status Verified: 2016-03
• Last Update Submitted: 2016-03-01
• Last Update Posted: 2016-03-03

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 8

Inclusion Criteria

• Diagnosis of Rheumatoid Arthritis based on the 2010 American College of Rheumatology (ACR)/European League against Rheumatism (EULAR) criteria, or ACR 1987 for patients with diagnosis prior 2011 ≥ 3 months.
• Except for methotrexate (MTX), the subject must have discontinued all disease modifying anti-rheumatic drugs (DMARD) for at least 5 half-lives before the first dose of study drug, and undergone cholestyramine washout if received Leflunomide within the past 3 months.
• Subject must have been on MTX therapy > 3 months and on a stable dose (7.5 - 25 mg/week), for at least 4 weeks prior to the first dose of study drug. Subject must be able to continue on stable dose of MTX for the duration of study participation.
• Body Mass Index (BMI) is 19 to 35, inclusive. (BMI is calculated as weight [kg] divided by height [m2].)
• Judged to be in good general health as determined by the Investigator based upon the results of medical history, laboratory profile, physical examination and 12-lead electrocardiogram (ECG) performed at screening

Exclusion Criteria

• Evidence of anti-ABBV-257 antibody results in a pre-study serum sample.
• History of significant allergic reaction or significant sensitivity to any constituents of the study drug; or history of anaphylactic reaction to any agent (e.g., food products and bee sting); or history of a major reaction to any Immunoglobulin G (IgG) containing product.
• History of persistent chronic or active infection(s) requiring hospitalization or treatment with intravenous or oral antimicrobials/antibiotics within 30 days prior to initial study drug administration.
• History or evidence of active tuberculosis (TB) or the subject has evidence of risk factor for latent TB.
• Clinically significant abnormal screening laboratory results as evaluated by the Investigator, including serum values of Aspartate aminotransferase (AST) or Alanine aminotransferase (ALT) greater than 2.25 × the upper limit of normal, or creatinine greater than 1.5 × the upper limit of normal, or absolute neutrophil count < 1500 μ/L.
• Subject has any medical condition or illness other than RA that is not well controlled with treatment that would, in the opinion of the investigator, preclude study participation or interfere with other symptoms of Rheumatoid Arthritis (RA).

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
low dose ABBV-257	ABBV-257	Low dose every other week (eow), Weeks 0-8
low dose ABBV-257	Placebo	Low dose every other week (eow), Weeks 0-8
Medium dose of ABBV-257	ABBV-257	Medium dose every other week (eow), Weeks 0-8
Medium dose of ABBV-257	Placebo	Medium dose every other week (eow), Weeks 0-8
high dose of ABBV-257	Placebo	high dose every other week (eow), Weeks 0-8
high dose of ABBV-257	ABBV-257	high dose every other week (eow), Weeks 0-8

Primary Outcome Measures

Name	Time	Method
Proportion of subjects with adverse events	Up to day 193	This will be collected through out the study
Maximum observed serum concentration (Cmax)	Up to day 50	This will be assessed using non-compartmental methods.
Change in Vital signs	From day 1 to day 193	Vital signs including blood pressure and heart rate will be assessed
Change in Physical examination	From day 1 to day 193	Changes in any physical exam assessed by the physician will be assessed.
Time to maximum observed serum concentration (Tmax)	Up to day 50	This will be assessed using non-compartmental methods.
Changes in Electrocardiogram (ECG)	From day 1 to day 193	ECG measurements will be assessed

Secondary Outcome Measures

Name	Time	Method
Immunogenicity by measurement of Anti-drug antibody	Up to day 193	Immunogenicity will be measured to see if the body has produced an immune response to ABBV-257

Trial Locations

Locations (1)

Site Reference ID/Investigator# 139394; 🇩🇪 Berlin, Germany